Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new battle plan against Post-Surgery pain rebound

NCT ID NCT06864312

Symptom relief Sponsor: University College Cork Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests two ways to prevent rebound pain—a sudden spike in pain after a nerve block wears off—following ankle fracture surgery. One approach uses a continuous infusion of a local anesthetic, while the other gives a timed dose of a painkiller. The study will compare these to standard care in 120 adults undergoing ankle surgery, measuring pain scores and recovery outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
levobupivacaine (continuous infusion) and oxycodone (timed oral dose)
What this could lead to
If successful, this could establish a standard approach to prevent severe rebound pain after ankle surgery, improving recovery and reducing opioid use.
What could go wrong
This is a single-center trial with 120 participants, so results may not apply broadly. Both interventions carry risks, such as infection or side effects from medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

120 people

The number who actually took part.

Started

Oct 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing surgery for ankle fracture ORIF receiving regional anaesthesia for postoperative analgesia. ASA Grades 1-3 Exclusion Criteria: * Pain preoperatively of any source requiring analgesic consumption (on more than three occasions) within three months of surgery. Open fractures Multiple injuries History of chronic pain syndrome. History of peripheral neuropathy. Clinically significant cognitive impairment (MiniMental state score \< 24) Severe cardiac, respiratory, renal or endocrine dysfunction Allergy to any of the following: Lignocaine, Bupivacaine, Paracetamol, Diclofenac, Oxycodone, Dexamethasone, Propofol, Vecuronium. Malignant Hyperthermia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankle fracture (bimalleolar equivalent, bimalleolar, or trimalleolar) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Ankle Fractures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankle fracture (bimalleolar equivalent, bimalleolar, or trimalleolar) Ankle fracture - lateral malleolus Ankle fracture - medial malleolus Rebound pain

Contacts and locations

Locations

  • Cork University Hospital

    Cork, Cork, P85 FR62, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.